Stockholm, Sweden, (May 19, 2026) – Life Science Newswire – Epigenica AB, a company commercializing advanced tools for epigenetic analysis, today announced an agreement with the National Genomics Infrastructure (NGI), one of the largest technical platforms at SciLifeLab. NGI Stockholm has become the first official core laboratory and service provider globally to offer Epigenica’s EpiFinder™ platform. This milestone represents a significant step in expanding access to high-throughput, multiplex epigenomic profiling to the research community.

As the first certified service provider, NGI will deliver end‑to‑end workflows using both EpiFinder™ cNuc (for histone and DNA methylation profiling of circulating nucleosomes in liquid biopsies) as well as EpiFinder™ GenomePro (for histone and DNA methylation profiling in cells and tissues), enabling scalable, reproducible, and highly robust epigenomic insights for projects of any size.

“Partnering with NGI marks the first step in scaling access to our epigenomic platforms,” said Mohamad Takwa, CEO of Epigenica. “By working with one of Europe’s leading genomics infrastructures, we are not only expanding availability of EpiFinder™ GenomePro and EpiFinder™ cNUC, but also establishing a model for how these technologies can be deployed more broadly. This collaboration lays the foundation for a growing network of partners and will support more consistent, high-quality epigenomic research at scale.” 

Through this collaboration, NGI users will gain access to:

• EpiFinder™ cNUC and EpiFinder™ GenomePro platforms providing multiplexed epigenomic profiling across plasma, serum, cells, and tissues, enabling powerful biomarker discovery through epigenetic signatures.
• Full project support, including study design consultation, sample preparation, sequencing, and downstream analysis.

“We are thrilled to be the first core facility certified to deliver Epigenica’s EpiFinder technologies,” said Anja Mezger, Head of Unit at NGI in Stockholm. “These platforms fill critical needs for researchers seeking high resolution epigenomic insights through streamlined workflows. With EpiFinder™ GenomePro and cNuc, we can offer even greater depth and capability within our service portfolio.”

This collaboration is part of Epigenica’s broader strategy to build a global network of dedicated certified service providers delivering harmonized, high-quality epigenomic data. Additional partner sites will be announced in due course as adoption of EpiFinder™ GenomePro and cNuc expands across academia, biopharma and pharmaceutical research.